Definitive Contract 75D30120C07996
Award Date
5/1/20
Potential Completion Date
7/7/21
Potential Value
$396K
Federal Agency
CDC Pittsburgh
Awardee
Stemexpress, LLC
Ultimate Awardee
Not listed
NAICS Category
621511 - Medical Laboratories
PSC Category
B537 - Special Studies/Analysis- Medical/Health
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Folsom, CA 95630, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
4
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Food and Drug Administration (FDA) awarded a $47,470.00 firm-fixed price purchase order contract to Stemexpress, LLC (doing business as CGT Global), a small disadvantaged woman-owned business, to provide human donor blood for the development of bioassays using peripheral blood mononuclear cells (PBMC) and/or isolated immune cells. The contract has an ultimate completion date of August 31, 2025 and does not utilize a set-aside. Stemexpress, a provider of human biological samples, has...
This federal contract award was granted to Stemcell Technologies Inc., a subsidiary of the Canadian biotechnology company Stemcell Technologies, by the Department of Health and Human Services (HHS). The contract, worth $24,908.80, is a firm fixed-price purchase order for the company to provide a range of specialized biological materials, laboratory supplies, scientific equipment, and proprietary products to support biomedical research initiatives across various HHS agencies, including the...
The Department of Health and Human Services Centers for Disease Control and Prevention in Pittsburgh awarded a $86,359.80 firm fixed price purchase order to Stemcell Technologies Inc. of Kent, Washington for laboratory reagents. The contract runs from July 19, 2023 through February 15, 2024 to support CDC's research and public health programs. As a leading supplier of cell biology reagents and tools, Stemcell will provide the requested products to aid CDC's disease prevention and health...
The Department of Health and Human Services Centers for Disease Control and Prevention awarded a Definitive Contract to Bioivt, LLC, a for-profit limited liability company, to provide COVID-19 positive blood serum. The Firm Fixed Price contract, valued at $370,350.00, has a completion date of April 28, 2021. Bioivt, LLC is a leading global provider of high-quality biological specimens and has previously supported various medical research programs across federal agencies, including the Defense...
The U.S. Centers for Disease Control and Prevention (CDC) awarded a $59,293.60 firm-fixed-price purchase order contract to Stemcell Technologies Inc., a subsidiary of the Canadian company Stemcell Technologies, to provide intesticult cell cultures. This contract, which has an ultimate completion date of October 8, 2025, is not set aside for small businesses. Stemcell Technologies Inc. is a key supplier of specialized biological materials, laboratory supplies, scientific equipment, and...
This federal contract award to Stemcell Technologies Inc., a Canadian biotechnology company, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a sub-agency of the U.S. Department of Health and Human Services (HHS). The $24,536.00 firm fixed-price purchase order is for the provision of the AMBIS 1787964 QUOTE Q-921198 item, which is described as the "EASY STEP NEGATIVE HUMAN CD4 KIT". The award does not have a small business set-aside designation. Stemcell...
This federal contract award was issued by the National Institute of Dental and Craniofacial Research (NIDCR), a civilian agency within the Department of Health and Human Services (HHS), to Stemcell Technologies Inc., a subsidiary of the Canadian company Stemcell Technologies. The $24,994.77 firm-fixed-price purchase order, awarded on November 6, 2019, is for the delivery of STEMDIFF APEL 2 MEDIUM, a specialized cell culture product used to support biomedical research initiatives. Stemcell...
The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $17,450.00 Firm Fixed Price purchase order contract to Stemcell Technologies Inc., a Canadian-owned for-profit organization, for the delivery of HUMAN CD8 KITS. The contract has a completion date of June 22, 2018 and does not have a set-aside designation. Stemcell Technologies Inc. is an active supplier of specialized biological materials, laboratory...
This is a firm fixed-price purchase order awarded to Stemcell Technologies Inc., a foreign-owned, for-profit biotechnology company, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services. The contract is for the delivery of specialized cell culture kits, including the STEMDIFF MICROGLIA DIFFERENTIATION KIT, STEMDIFF MICROGLIA MATURATION KIT, and STEMDIFF HEMATOPOETIC...
<p>The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response, awarded a $93,510.00 firm-fixed-price purchase order to Cantor Bioconnect for the delivery of COVID-19 serum samples. The contract, which was not set aside, had an award date of May 6, 2020 and an ultimate completion date of June 5, 2020. This contract award was not associated with a larger contract vehicle.</p>